IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

(in CHF 1 000)

 

 

Notes

 

01.01.–30.09.2021

 

01.01.–30.09.2020

 

01.07.–30.09.2021

 

01.07.–30.09.2020

Operating income

 

 

 

 

 

 

 

 

 

 

Net gains from securities

 

4

 

187 170

 

61 703

 

 

Interest income

 

 

 

 

7

 

 

Dividend income

 

 

 

 

243

 

 

Other income

 

 

 

4

 

21

 

 

18

 

 

 

 

187 174

 

61 974

 

 

18

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Net losses from securities

 

4

 

 

 

(192 643)

 

(382 803)

Finance expenses

 

 

 

(648)

 

(683)

 

(251)

 

(192)

Foreign exchange losses

 

 

 

(623)

 

(429)

 

(149)

 

(425)

Administrative expenses

 

7

 

(39 806)

 

(30 690)

 

(13 821)

 

(10 902)

Other expenses

 

 

 

(4 943)

 

(3 632)

 

(1 515)

 

(896)

 

 

 

 

(46 020)

 

(35 434)

 

(208 379)

 

(395 218)

Profit/(loss) before tax

 

8

 

141 154

 

26 540

 

(208 379)

 

(395 200)

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(57)

 

(51)

 

(19)

 

(17)

Profit/(loss) for the period

 

 

 

141 097

 

26 489

 

(208 398)

 

(395 217)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

141 097

 

26 489

 

(208 398)

 

(395 217)

 

 

 

 

 

 

 

 

 

 

 

Earnings/(loss) per share in CHF

 

 

 

2.55

 

0.48

 

(3.76)

 

(7.13)

Diluted earnings/(loss) per share in CHF

 

 

 

2.55

 

0.48

 

(3.76)

 

(7.13)

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer